Gilead Sciences, Inc. GILD
169.53 USD -0.20 (-0.12%)
Nov 12, 2026, 2:14 PM EST
169.00 Day range 171.70
118.30 52-week range 174.48
- YTD
- +38.12%
- 1 year
- +37.38%
News
zacks.com Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth? GILD's HIV franchise gains momentum as Yeztugo sales surge, Biktarvy maintains market leadership and an expanding pipeline strengthens long-term growth prospects.
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
seekingalpha.com Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
marketbeat.com Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch Gilead Sciences NASDAQ: GILD is preparing for a potential launch of its multiple myeloma cell therapy anito-cel, with plans to build on the treatment-center relationships and manufacturing…
fool.com Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy? The healthcare company's growth rate has been showing significant improvement in recent periods. Its diversified business has been generating positive growth across multiple therapeutic areas.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Gilead Highlights Strong Trial Results in HIV Prevention and Liver Disease Gilead reports high persistence for twice-yearly HIV shot lenacapavir and strong Phase 3 Livdelzi response in primary biliary cholangitis.
fool.com The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation These are among the best the industry has to offer.
247wallst.com Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe? A red ink EPS figure usually spells trouble for retirees counting on a payout. Gilead's loss traces back to one strange quarter, and a single cash metric reveals whether the dividend checks are…
benzinga.com Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.47% on an annualized basis producing an average annual return of 12.13%. Currently, Gilead Sciences has a market…
benzinga.com Gilead’s Twice-Yearly HIV Prevention Injection Shows 85.6% Persistence And Zero HIV Acquisitions in 52-Week Trial Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from the PURPOSE 5 trial showing significantly higher persistence—defined as consistent and continuous on-time use—among people starting…
benzinga.com Gilead Sciences Reports Phase 3 IDEAL Success For Livdelzi In PBC, With 75.4% Achieving ALP Normalization At Week 52 Vs 16.1% Placebo; Serious Adverse Events 3.1% Livdelzi Vs 12.9% Placebo; None Related To Drug - Data to be Presented at The Liver Meeting® Demonstrate Rapid and Sustained Improvements in ALP Levels with Livdelzi in Adults with PBC and ALP Levels Between 1-1.67× ULN, Despite Receiving UDCA or…
businesswire.com Positive Phase 3 IDEAL Study Results Further Support Livdelzi®'s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants…
fool.com Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. Gilead's HIV therapies generate strong free cash flow. The company is successfully branching out into oncology and anti-inflammatory therapies.
defenseworld.net Ascent Group LLC Sells 7,256 Shares of Gilead Sciences, Inc. $GILD Ascent Group LLC cut its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 11.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The…
benzinga.com Gilead Sciences To Present 23 Presentations At 68th American Society of Hematology Annual Meeting Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH)…
benzinga.com Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.29% on an annualized basis producing an average annual return of 12.2%. Currently, Gilead Sciences has a market…
benzinga.com JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190 JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.- benzinga.com TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175 TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $160 to $175.
benzinga.com Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183 Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.- benzinga.com Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190 Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $165 to $190.
- benzinga.com Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181 Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.
- benzinga.com RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131 RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $126 to $131.
benzinga.com Gilead CEO Takes Aim at Medicare Pricing: 'Pill Penalty' Threatens Drug Innovation Gilead stock rose after Q3 earnings beat Wall Street estimates and strong HIV drug demand prompted an increased 2026 sales forecast.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.- benzinga.com These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results Gilead beats Q3 estimates, raises 2026 sales guidance but cuts EPS outlook; shares rise 4.1% as analysts lift price targets.
benzinga.com Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $175 Cantor Fitzgerald analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $155 to $175.- benzinga.com Needham Maintains Buy on Gilead Sciences, Raises Price Target to $200 Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $170 to $200.
benzinga.com Gilead Sciences Q3 2026 Earnings Call Transcript Gilead Sciences (NASDAQ:GILD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.75)-$(3.40) to $(4.40)-$(4.05) vs $(3.44) Est Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.75)-$(3.40) to $(4.40)-$(4.05) vs $(3.44) analyst estimate..- benzinga.com Gilead Sciences Lowers FY2026 Adj EPS Guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85) vs $(0.47) Est; Raises FY2026 Sales Guidance from $30.100B-$30.400B to $31.000B-$31.300B vs $30.767B Est Gilead Sciences (NASDAQ:GILD) lowers FY2026 Adj EPS guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85) vs $(0.47) analyst estimate. Raises FY2026 sales outlook from $30.100 billion-$30.400 billion to…
- benzinga.com Gilead Sciences Q3 Adj. EPS $2.55 Beats $2.19 Estimate, Sales $8.300B Beat $7.809B Estimate Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.19 by 16.44 percent. This is a 3.24 percent increase over earnings of…
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Gilead Sciences Agrees To Acquire Oral IL-23R Inhibitor Program From PepStar Therapeutics Under $1.275B Deal Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar…
benzinga.com BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb ("BMS").ROSETTA…
benzinga.com Occidental Petroleum To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts cut targets for WING, ELAN, SBAC and RH; raised targets for TRV, OXY and GILD, with ELAN downgraded to Hold.- benzinga.com B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172 B of A Securities analyst Tim Anderson maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $168 to $172.
benzinga.com Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success Gilead Sciences announced positive Phase 2 SWIFT trial results for emvistegrast, an oral treatment for active ulcerative colitis.
benzinga.com Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.- benzinga.com Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked TCE development candidates targeting selected solid…
- benzinga.com Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens - Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and…
benzinga.com $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.27% on an annualized basis producing an average annual return of 11.34%. Currently, Gilead Sciences has a market…- benzinga.com RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126 RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $123 to $126.
- benzinga.com Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
- benzinga.com Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158 Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.
- benzinga.com JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170 JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.
- benzinga.com Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163 Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.